Fu Hong Han Lin (02696) will be officially included in the Hong Kong Stock Connect today to combine multiple capital benefits and commercialization of globalization to enter a harvest period

According to the Zhitong Finance App, according to the “Notice Concerning the Adjustment of the Shanghai-Hong Kong Stock Exchange” issued by the Shanghai Stock Exchange on September 4, 2026 and the “Notice Concerning the Adjustment of the Hong Kong Stock List under the Shenzhen-Hong Kong Stock Connect Securities List” issued by the Shenzhen Stock Exchange on September 7, 2026, Fu Hong Han Lin (02696) was transferred to the securities list of Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, which will officially take effect on September 7, 2026. After inclusion, eligible mainland Chinese investors can directly invest in the company's shares through the Shanghai Stock Exchange and Shenzhen Stock Exchange respectively. This inclusion will help the company expand its shareholder base and enhance the trading liquidity of the company's shares, thereby further increasing the company's investment value in the capital market.

In 2026, the company successively ushered in capital market milestones. The company completed full circulation of H shares in February, and the H share circulation ratio rose to 63.68%. In August, it was successively included as a component stock of the MSCI China Small Cap Index and a component stock of the Hang Seng Composite Index. Along with the optimization of the equity structure and the opening of the Hong Kong Stock Connect, the company's stock liquidity is expected to increase, further attracting high-quality capital at home and abroad. As of the close of trading on September 4, 2026, the company's stock price increased by about 22.87%, with a total market value of HK$38.2 billion; from June to September 2026, more than 10 new brokerage firms all gave the company a “buy/increase” rating. Institutions such as Goldman Sachs, Citibank, and CICC are optimistic about the implementation of their global commercialization capabilities and innovation pipeline, and acknowledge that the medium- to long-term growth logic is clear.

Up to now, 10 Fuhong Hanlin products have been approved for marketing in more than 60 countries and regions around the world, covering a wide range of Asia, Europe, Latin America, North America and Oceania, benefiting more than 1.1 million patients. In the first half of 2026, the company achieved revenue of 3,588.2 billion yuan, up 27.3% year on year; net profit of 430.4 million yuan, up 10.3% year on year; global product sales revenue reached 2,9386 million yuan, up 14.9% year on year; overseas product sales revenue increased 159.4% year on year to 105.3 billion yuan, and overseas product profit reached 595 million yuan, more than four times the same period last year, and global commercialization entered a profitable harvest period.